In summary, HQT may interfere with PERK and ATF6 signaling pathway protein expression to reduce the intensity of ERS, attenuate the hepatocyte inflammatory response, and mitigate the progression of NAFLD. The gene discussed is ATF6; the disease is metabolic dysfunction-associated steatotic liver disease.